Molecular subtypes identified by gene expression profiling in early stage endometrioid endometrial adenocarcinoma

作     者：GAO Bao-rong CHEN Yong-hua YAO Yuan-yang LI Xiao-ping WANG jian-liu WEI Li-hui 

作者机构：Department of Obstetrics and Gynecology Peking UniversityPeople's Hospital Beijing 100044 China 

出 版 物：《Chinese Medical Journal》 (中华医学杂志（英文版）)

年 卷 期：2013年第126卷第19期

页      面：3680-3684页

核心收录：

学科分类：0710[理学-生物学] 1002[医学-临床医学] 07[理学] 08[工学] 09[农学] 071007[理学-遗传学] 0901[农学-作物学] 0836[工学-生物工程] 090102[农学-作物遗传育种] 

基　　金：国家教育部高等学校博士学科点专项科研基金 

主　　题：endometrioid adenocarcinoma molecular classification gene expression profiling risk factor 

摘      要：Background Early stage （FIGO stage Ⅰ-Ⅱ） endometrioid endometrial adenocarcinoma （EEA） is very common in clinical ***,patients with the early stage EEA show various clinical behaviors due to biological ***,we aimed to discover distinct classes of tumors based on gene expression profiling,and analyze whether the molecular classification correlated with the histopathological stages or other clinical *** Hierarchical clustering was performed for class discovery in 28 eady stage EEA samples using a special cDNA microarray chip containing 492 genes designed for endometrial *** between clinicopathologic parameters and our classification were *** the significance analysis of microarrays （SAM） array was used to identify the signature genes according to the tumor grade and myometrial *** Three tumor subtypes （subtypes Ⅰ,Ⅱ and Ⅲ） were identified by hierarchical clustering,each subtype had different clinicopathological factors,such as tumor grade,myometrial invasion status,and FIGO ***,SAM analysis showed 34 up-regulated genes in high grade tumors,and 38 up-regulated genes and 1 down-regulated in deep myometrial invasive *** overlap genes between these two high-risk factors were markedly up-regulated in subtype Ⅰ,but down-regulated in subtype Ⅲ.Conclusion We have identified novel molecular subtypes in early stage *** gene signatures characterize each tumor subtype,which could be used for recognizing the tumor risk and providing a basis for further treatment stratification.